Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results of 2-year follow-up

• T. I. Ionova,
• T. P. Nikitina,
• E. G. Lomaia,
• G. B. Kuchma,
• E. R. Machyulaytene,
• E. I. Usacheva,
• T. V. Shnaider,
• A. Yu. Rodionova,
• K. A. Kurbatova

Affiliations

T. I. Ionova

N.I. Pyrogov National Medical-Surgical Center; Multinational Center for Quality of Life Research

T. P. Nikitina

N.I. Pyrogov National Medical-Surgical Center; Multinational Center for Quality of Life Research

E. G. Lomaia

Northwest Federal Medical Research Center, Ministry of Health of Russia

G. B. Kuchma

Orenburg State Medical Academy

E. R. Machyulaytene

Policlinic № 31 of I.P. Pavlov St. Petersburg State Medical University

E. I. Usacheva

R. M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, I.P. Pavlov St. Petersburg State Medical University

T. V. Shnaider

Regional Hospital, St. Petersburg

A. Yu. Rodionova

Multinational Center for Quality of Life Research

K. A. Kurbatova

Multinational Center for Quality of Life Research